At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 155 enrolled
Drug / intervention
JZP258drug
Likely dose
JZP258 0.5 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to Xywav
In Brief
A Phase 4 clinical trial evaluating JZP258 for Narcolepsy. Completed, enrolled 155 participants across 43 sites in 5 countries.
Detailed Summary
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to Xywav, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNarcolepsy
CountriesBelgium, France, Italy, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionFeb 2025
Study CompletionMar 2025
TodayJul 2026
First PostedMay 22, 2023
Enrollment StartJun 26, 2023
Primary CompletionFeb 25, 2025
Study CompletionMar 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.1 years ago
Interventions
JZP258drug
0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution